NewAmsterdam Pharma Company announced the appointment of Ian Somaiya as Chief Financial Officer, CFO. Somaiya is an established healthcare executive with extensive financial and operational expertise, including over two decades of experience on Wall Street as a prominent biotechnology research analyst. Somaiya most recently served as CFO and Chief Business Officer of Elucida Oncology.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NAMS:
- NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer
- NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation
- NewAmsterdam announces initial date from Phase 2a trial of obicetrapib